Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma

Tarek H. Mouhieddine; Samir Parekh; Hearn Jay Cho; Joshua Richter; Andrew DeCastro; Jatin Shah; Yosef Landesman; Ajai Chari; Sundar Jagannath; Deepu Madduri

doi:10.1007/s00277-020-04293-y

Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma

Tarek H. Mouhieddine, Samir Parekh, Hearn Jay Cho, Joshua Richter, Andrew DeCastro, Jatin Shah, Yosef Landesman, Ajai Chari, Sundar Jagannath, Deepu Madduri

Research output: Contribution to journal › Letter › peer-review

2 Scopus citations

Original language	English
Pages (from-to)	3057-3060
Number of pages	4
Journal	Annals of Hematology
Volume	100
Issue number	12
DOIs	https://doi.org/10.1007/s00277-020-04293-y
State	Published - Dec 2021

Access to Document

10.1007/s00277-020-04293-y

Cite this

@article{185e83c9d2d44b19bdf319dc967a212e,

title = "Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma",

author = "Mouhieddine, {Tarek H.} and Samir Parekh and Cho, {Hearn Jay} and Joshua Richter and Andrew DeCastro and Jatin Shah and Yosef Landesman and Ajai Chari and Sundar Jagannath and Deepu Madduri",

note = "Funding Information: S.P. received consulting fees from Foundation Medicine and research funding from Celgene and Karyopharm Therapeutics. H.J.C. received commercial research support from Genentech Roche, Celgene and Takeda, and compensation for consulting/advisory boards from Genentech Roche, Celgene, Bristol-Myers Squibb and GalaxoSmithKline, and is employed by the Multiple Myeloma Research Foundation. J.R. received speaking fees from Celgene and Janssen and an advisory board and consulting fees from Celgene, Janssen, Bristol-Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm Therapeutics, and Antengene. A.D. is an employee and stockholder of Karyopharm Therapeutics. J.S. is an executive and stockholder of Karyopharm Therapeutics. Y.L. is a senior VP and stockholder of Karyopharm Therapeutics. A.C. received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm Therapeutics, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, and Sanofi and has received research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals and Pharmacyclics. S. J. received advisory board fees and consulting fees from AbbVie, Celgene, Bristol-Myers Squibb, Karyopharm Therapeutics, Janssen Pharmaceuticals and Merck. D.M. received consulting fees from Janssen, Celgene, AbbVie, Takeda and Foundation Medicine. T.H.M. declares no potential conflict of interest. Funding Information: This study was funded by Karyopharm Therapeutics. ",

year = "2021",

month = dec,

doi = "10.1007/s00277-020-04293-y",

language = "English",

volume = "100",

pages = "3057--3060",

journal = "Annals of Hematology",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "12",

}

TY - JOUR

T1 - Selinexor, bortezomib, and dexamethasone (SVD) in heavily treated relapsed refractory multiple myeloma

AU - Mouhieddine, Tarek H.

AU - Parekh, Samir

AU - Cho, Hearn Jay

AU - Richter, Joshua

AU - DeCastro, Andrew

AU - Shah, Jatin

AU - Landesman, Yosef

AU - Chari, Ajai

AU - Jagannath, Sundar

AU - Madduri, Deepu

N1 - Funding Information: S.P. received consulting fees from Foundation Medicine and research funding from Celgene and Karyopharm Therapeutics. H.J.C. received commercial research support from Genentech Roche, Celgene and Takeda, and compensation for consulting/advisory boards from Genentech Roche, Celgene, Bristol-Myers Squibb and GalaxoSmithKline, and is employed by the Multiple Myeloma Research Foundation. J.R. received speaking fees from Celgene and Janssen and an advisory board and consulting fees from Celgene, Janssen, Bristol-Myers Squibb, Oncopeptides, Adaptive Biotechnologies, X4 Pharmaceuticals, Karyopharm Therapeutics, and Antengene. A.D. is an employee and stockholder of Karyopharm Therapeutics. J.S. is an executive and stockholder of Karyopharm Therapeutics. Y.L. is a senior VP and stockholder of Karyopharm Therapeutics. A.C. received honoraria from Amgen, Antengene, Celgene, Janssen, Karyopharm Therapeutics, Millennium/Takeda, Novartis Pharmaceuticals, Oncopeptides, and Sanofi and has received research funding from Amgen, Celgene, Janssen, Millennium/Takeda, Novartis Pharmaceuticals and Pharmacyclics. S. J. received advisory board fees and consulting fees from AbbVie, Celgene, Bristol-Myers Squibb, Karyopharm Therapeutics, Janssen Pharmaceuticals and Merck. D.M. received consulting fees from Janssen, Celgene, AbbVie, Takeda and Foundation Medicine. T.H.M. declares no potential conflict of interest. Funding Information: This study was funded by Karyopharm Therapeutics.

PY - 2021/12

Y1 - 2021/12

UR - http://www.scopus.com/inward/record.url?scp=85091760881&partnerID=8YFLogxK

U2 - 10.1007/s00277-020-04293-y

DO - 10.1007/s00277-020-04293-y

M3 - Letter

C2 - 33009581

AN - SCOPUS:85091760881

SN - 0939-5555

VL - 100

SP - 3057

EP - 3060

JO - Annals of Hematology

JF - Annals of Hematology

IS - 12

ER -